Craig Lipset’s Post

During the Digital Health & AI Innovation Summit (DHAI), Craig Lipset needed a therapy session. So we sat down to talk about the intersection of #pharma and #digitalhealth. 🎥 See a glimpse below. 🎥 On a serious note, here are some of the key points: 🎥 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐑𝐢𝐬𝐤 𝐀𝐯𝐞𝐫𝐬𝐢𝐨𝐧 𝐒𝐥𝐨𝐰𝐬 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: the pace of innovation in pharmaceutical companies is too slow, particularly in clinical trials and digital health. 🎥 𝐋𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐍𝐞𝐞𝐝𝐬 𝐭𝐨 𝐃𝐫𝐢𝐯𝐞 𝐂𝐡𝐚𝐧𝐠𝐞: this means taking bold steps to implement digital solutions and setting clear targets. 🎥 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 𝐀𝐫𝐞 𝐍𝐨𝐭 𝐭𝐡𝐞 𝐌𝐚𝐢𝐧 𝐁𝐚𝐫𝐫𝐢𝐞𝐫: While regulations are often blamed for delaying innovation, Craig argues that they are not the primary obstacle. 🎥 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐚𝐧𝐝 𝐀𝐈: There is enormous potential for AI and digital tools to improve clinical trials, streamline processes, and enhance patient engagement. 🎥 𝐏𝐚𝐭𝐢𝐞𝐧𝐭-𝐋𝐞𝐝 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐬 𝐑𝐢𝐬𝐢𝐧𝐠: pharma companies should either keep up or let these smaller, more agile organizations take the lead. 🎥 𝐔𝐫𝐠𝐞𝐧𝐜𝐲 𝐟𝐨𝐫 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧: pharma industry should act with greater urgency in adopting digital health solutions, as patients expect and need faster innovation. Tune in to the full discussion on Faces Of Digital Health Podcast Youtube: https://lnkd.in/deHaCUit #digitalhealth #pharma #AI #clinicaltrials Gil Bashe, next time we are going to have a joint discussion! Amir Lahav congrats again on a very delightful event with a charming vibe.

This Friday on TGIF-DTRA! Donna O'Brien and Rachel Sher lead much of Manatt, Phelps & Phillips, LLP’s work on clinical trials, including some recent work on expanding access and enrollment for clinical trials in academic centers. We look forward to discussing how these centers are driving innovation back into clinical trials. Join us on Friday at 12:00 PM ET for the discussion.

It's a TGIF-DTRA + Real World Wednesday's Crossover Episode! With the release of the FDA Draft Guidance on Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice, it was the perfect topic to bring together the DCT and RWE community for a conversation around this guidance. Join us for a discussion around why this guidance was aligned to RWE, the distinctions between decentralized, pragmatic, point-of-care trials, and real-world evidence, and how RCTs and DCTs can drive access for all patients. Read the guidance here --> https://lnkd.in/e72JDuvj Learn more about Real World Wednesday's here --> https://rwd-rwe.club/ AMIR KALALI, MD Craig Lipset Jane Myles Matt Veatch Aaron Kamauu MD MS MPH

This Friday on TGIF-DTRA! Donna O'Brien and Rachel Sher lead much of Manatt, Phelps & Phillips, LLP’s work on clinical trials, including some recent work on expanding access and enrollment for clinical trials in academic centers. We look forward to discussing how these centers are driving innovation back into clinical trials. Join us on Friday at 12:00 PM ET for the discussion.

It's a TGIF-DTRA + Real World Wednesday's Crossover Episode! With the release of the FDA Draft Guidance on Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice, it was the perfect topic to bring together the DCT and RWE community for a conversation around this guidance. Join us for a discussion around why this guidance was aligned to RWE, the distinctions between decentralized, pragmatic, point-of-care trials, and real-world evidence, and how RCTs and DCTs can drive access for all patients. Read the guidance here --> https://lnkd.in/e72JDuvj Learn more about Real World Wednesday's here --> https://rwd-rwe.club/ AMIR KALALI, MD Craig Lipset Jane Myles Matt Veatch Aaron Kamauu MD MS MPH